|
|
The present Competitive Intelligence Report about CEA Antagonists provides a competitor evaluation in the field of investigational antibodies and vaccines targeting carcinoembryonic antigen (CEA) for treatment of cancer as of April 2009. The report includes a compilation of current active projects in research and development of epithelial cell adhesion molecule (EpCAM) targeting antibodies and antibody-based constructs. In addition, the report lists company-specific R&D pipelines of EpCAM Antagonists. Competitor projects are listed in a tabular format providing information on:
|
Additional Information
Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations.
